Neurología

A continuación se enumeran ensayos clínicos actuales.

Filtrar esta lista de estudios según la ubicación, el estado del estudio y más.

1. Natural History Study Protocol in PMM2-CDG (CDG-Ia)

   Rochester, Minn.

   Clinical and Basic Investigations into Phosphomannomutase deficiency (PMM2-CDG) This is a natural history (observational) protocol designed to collect clinical and biological information in patients with PMM2-CDG (CDG-Ia). Data from this natural history study will be used to determine a set of clinical and biological parameters that will be used for primary and secondary endpoints in a later clinical trial with a new chemical entity, Lipo-M1P.

2. The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech

   Rochester, Minn.

   The purpose of this study is to identify and distinguish two different types of Progressive Apraxia of Speech through clinical imaging and testing.

3. A Study to Evaluate Safety of Long-term AL001 Dosing in FTD Patients

   Rochester, Minn.

   The puppse pf tjos stidu os tp evaluate the safety, tolerability, pharmacokinets (PK) and pharmacodynamics (PD) of AL001 in participants with a Granulin mutation or C9orf72 mutation causative of frontotemporal dementia.

4. A Study to Test the Effectiveness and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects with Drug-resistant Epilepsy

   Rochester, Minn.

   The purpose of the study is to evaluate the effectiveness, safety and tolerability of the 3 selected dose regimens of padsevonil (PSL) administered simultaneously with up to 3 anti-epileptic drugs (AEDs) compared with placebo for treatment of observable focal-onset seizures in adult subjects with drug-resistant epilepsy.

5. Non-invasive Diagnostic for Assessing Elevated Intracranial Pressure

   Rochester, Minn.

   The study is a prospective, multi-center, non-randomized, open label observational study. The objective of this study is to compare the accuracy of the EyeBOX to a clinical diagnosis of abnormal ICP as determined by an external ventriculostomy drain (EVD) or ventriculostomy catheter.

6. Investigation of Regulatory Genes in Pathophysiology of Craniosynostosis

   Rochester, Minn.

   The purpose of this study is to collect tissue (during the initial procedure only) that is surgically removed (and routinely discarded at Mayo Clinic) from CS patients. Portions of the tissue will be embedded in plastic for histological and histomorphometric analysis. A small portion of the tissue will be used for outgrowth cultures to isolate cells. Nucleic acid and protein will be extracted from the remaining portions of the tissue and/or isolated cell lines to examine candidate genes and their role in the disease process.

7. Study to Determine the Impact of Advanced Magnetic Resonance Imaging (MRI) Using 18F-DOPA (a chemical tracer that highlights certain cells during imaging) During Planning for Proton Beam Radiation Therapy.

   Scottsdale/Phoenix, Ariz., Rochester, Minn.

   The purpose of this study is to utilize a novel approach of combining advanced radiation delivery with proton beam therapy with advanced tumor visualization with 18F-DOPA PET and MRI imaging. We will study the effectiveness and safety of this technique delivering the entire treatment over 1-2 weeks.

8. A Study to Evaluate Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Patients

   Rochester, Minn.

   The purpose of this study is to evaluate, jointly and independently among patients deemed at higher risk vs. lower risk for disability accumulation, whether an "early aggressive" therapy approach, versus starting with a traditional, first-line therapy, influences the intermediate-term risk of disability, and to evaluate if, among patients deemed at lower risk for disability who start on first-line MS therapies but experience breakthrough disease, those who switch to a higher-efficacy versus a new first-line therapy have different intermediate-term risk of disability.FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early aggressive therapy with respect to preventing long-term disability. The infectious risks and other complications associated with higher-efficacy treatments highlight the need to quantify their effectiveness in preventing disability. The TRaditional versus Early Aggressive Therapy for MS (TREAT-MS) trial is a pragmatic, randomized controlled trial that has two primary aims:

9. Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma

   Rochester, Minn.

   This phase II trial studies how well reduced doses of radiation therapy to the brain and spine (craniospinal) and chemotherapy work in treating patients with newly diagnosed type of brain tumor called WNT)/Wingless (WNT)-driven medulloblastoma. Recent studies using chemotherapy and radiation therapy have been shown to be effective in treating patients with WNT-driven medulloblastoma. However, there is a concern about the late side effects of treatment, such as learning difficulties, lower amounts of hormones, or other problems in performing daily activities. Radiotherapy uses high-energy radiation from x-rays to kill cancer cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, vincristine sulfate, cyclophosphamide and lomustine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving reduced craniospinal radiation therapy and chemotherapy may kill tumor cells and may also reduce the late side effects of treatment.

10. A Study of Atrial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke

    Jacksonville, Fla.

    The primary purpose of this study is to test the theory that Eliquis (apixaban) is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy.